ArticleVaccine2023

Comparison of the safety and persistence of immunogenicity of bivalent HPV16/18 vaccine in healthy 9-14-year-old and 18-26-year-old Chinese females: A randomized, double-blind, non-inferiority clinical trial.

Juan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.